Anthem Biosciences Ltd Upgraded to Hold on Technical and Financial Reassessment

Technical Trend Shift Spurs Upgrade

The primary catalyst for the rating upgrade is the marked improvement in Anthem Biosciences’ technical profile. The technical grade has shifted from mildly bearish to mildly bullish, supported by several key indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) now signals a mildly bullish momentum, while Bollinger Bands also reflect a bullish stance. The Dow Theory confirms this trend with mildly bullish readings on both weekly and monthly charts.

However, some technical signals remain neutral or mixed. The Relative Strength Index (RSI) on a weekly basis shows no clear signal, and the On-Balance Volume (OBV) remains bearish weekly, indicating some caution among traders. Despite these nuances, the overall technical momentum has improved sufficiently to warrant a more optimistic rating.

Price action supports this technical shift, with the stock closing at ₹742.00 on 13 April 2026, up 2.98% from the previous close of ₹720.50. The stock is trading comfortably above its 52-week low of ₹579.45, though still below its 52-week high of ₹873.25, suggesting room for upside if momentum sustains.

Quality Assessment: Strong Management Efficiency Amidst Profit Pressure

Anthem Biosciences maintains a high-quality profile in terms of management efficiency, reflected in a robust Return on Equity (ROE) of 19.93%. This figure underscores the company’s ability to generate significant returns on shareholder capital, a key metric favouring long-term investors. The company’s low average Debt to Equity ratio of zero further enhances its quality standing, indicating a conservative capital structure with minimal financial leverage risk.

Nevertheless, the company reported a disappointing financial performance in the third quarter of FY25-26. Profit Before Tax excluding other income (PBT less OI) declined by 24.2% to ₹122.31 crores compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) fell by 14.1% to ₹110.87 crores, while net sales dropped to ₹423.15 crores, the lowest in recent quarters. These results highlight short-term operational challenges that temper the otherwise strong quality metrics.

Valuation: Elevated Price to Book Ratio Raises Concerns

Despite solid fundamentals, Anthem Biosciences carries a very expensive valuation. The stock trades at a Price to Book (P/B) ratio of 14.6, which is high relative to industry peers and historical averages. This elevated valuation reflects investor expectations for continued growth but also increases downside risk if earnings momentum falters.

While the company’s ROE of 17.7% justifies a premium to some extent, the valuation premium appears stretched given the recent quarterly profit decline. Investors should weigh this expensive valuation against the company’s healthy long-term growth trajectory, which includes a net sales compound annual growth rate (CAGR) of 29.80% and operating profit growth of 44.32% over recent years.

Financial Trend: Mixed Signals from Recent Quarterly Results

Anthem Biosciences’ financial trend presents a nuanced picture. On one hand, the company has demonstrated strong long-term growth, with net sales and operating profits expanding at impressive annual rates. On the other hand, the latest quarterly results reveal a setback, with declines in key profitability metrics and sales volume.

Year-to-date (YTD) stock returns have been robust at 13.97%, significantly outperforming the Sensex, which has declined by 9.00% over the same period. The one-month return of 10.75% and one-week return of 12.22% also outpace the benchmark index, signalling renewed investor interest despite recent earnings weakness.

However, the absence of a one-year return figure and the lack of longer-term stock return data suggest limited historical price appreciation visibility. This makes it essential for investors to monitor upcoming quarterly results closely to confirm whether the recent profit dip is a temporary aberration or indicative of a broader trend.

Technicals: Mildly Bullish Momentum Supports Positive Outlook

The upgrade to Hold is strongly supported by the improved technical outlook. Weekly MACD and Bollinger Bands have turned bullish, and the Dow Theory confirms a mildly bullish trend on both weekly and monthly timeframes. These indicators suggest that the stock’s price momentum is gaining strength, potentially attracting more buyers in the near term.

Nonetheless, some caution is warranted as the weekly OBV remains bearish, indicating that volume trends have yet to fully confirm the price strength. The RSI’s neutral stance also suggests the stock is not yet overbought, leaving room for further upside but signalling that momentum is not yet overwhelming.

Overall, the technical signals have improved enough to justify the rating upgrade from Sell to Hold, reflecting a more balanced risk-reward profile.

Outlook and Investor Considerations

Anthem Biosciences’ upgrade to Hold reflects a cautious optimism grounded in improved technical momentum and strong management efficiency. The company’s conservative capital structure and healthy long-term growth rates provide a solid foundation for future performance. However, investors should remain mindful of the recent quarterly profit decline and the stock’s elevated valuation, which could limit near-term upside.

Comparatively, Anthem has outperformed the Sensex significantly in the short term, with a 12.22% return over the past week and 13.97% YTD, underscoring renewed market interest. Yet, the lack of a one-year return figure and the recent earnings dip suggest that the stock remains vulnerable to volatility.

Given these factors, the Hold rating is appropriate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk profile. Those with a higher risk tolerance may consider monitoring technical signals closely for a potential upgrade to Buy, while more conservative investors might await clearer signs of earnings recovery before increasing exposure.

Promoters continue to hold a majority stake, which typically aligns management interests with shareholders, adding a layer of governance confidence.

Summary of Key Metrics

• Mojo Score: 50.0 (Hold, upgraded from Sell on 10 Apr 2026)
• Market Cap Grade: Mid-cap
• ROE: 19.93%
• Debt to Equity: 0 (average)
• Net Sales Growth (Annual): 29.80%
• Operating Profit Growth (Annual): 44.32%
• Price to Book Value: 14.6 (Very Expensive)
• Q3 FY25-26 PBT less OI: ₹122.31 crores (-24.2%)
• Q3 FY25-26 PAT: ₹110.87 crores (-14.1%)
• Stock Price (13 Apr 2026): ₹742.00 (+2.98%)
• 52 Week Range: ₹579.45 - ₹873.25

Investors should continue to monitor Anthem Biosciences’ upcoming quarterly results and technical developments to reassess the stock’s trajectory within the Pharmaceuticals & Biotechnology sector.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today